Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Technetium Tc 99m Mertiatide
Generic Name
Technetium Tc 99m Mertiatide
Active Ingredient
BetiatideCategory
Other
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 1 mg/1 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | INTRAVENOUS | 65174-261 |
Detailed information about Technetium Tc 99m Mertiatide
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Technetium Tc 99m Mertiatide, you must consult a qualified healthcare professional.
Betiatide is a diagnostic ligand used to prepare Technetium Tc-99m Mertiatide, a radiopharmaceutical essential for evaluating renal function, blood flow, and urinary tract obstruction through scintigraphic imaging.
The standard adult dose for Technetium Tc-99m Mertiatide (prepared from Betiatide) typically ranges from 185 to 370 Megabecquerels (MBq), which is equivalent to 5 to 10 millicuries (mCi). The exact activity administered is determined by the nuclear medicine physician based on the specific type of scan being performed and the patient's body weight. For a standard dynamic renal scan, a 5 mCi dose is common, whereas a higher dose may be used if the patient has significantly impaired kidney function to ensure the camera can capture enough signal for a clear image.
Betiatide is frequently used in children because it provides excellent image quality with a relatively low radiation dose. Pediatric dosing is strictly weight-based. Healthcare providers often follow the North American Consensus Guidelines or the European Association of Nuclear Medicine (EANM) dosage cards. The typical pediatric dose ranges from 2.6 to 5.2 MBq per kilogram (MBq/kg) of body weight, with a minimum recommended dose (often around 1 mCi) to ensure the scan is diagnostic. Your pediatric specialist will calculate the lowest possible dose necessary to obtain high-quality medical information.
No downward adjustment of the radioactive dose is typically required for patients with renal impairment; in fact, a slightly higher dose within the approved range may be used to compensate for the slower clearance of the drug and to improve image visualization. However, the time the patient spends under the camera may be extended to capture the delayed movement of the tracer.
Since the drug is cleared almost exclusively by the kidneys, hepatic (liver) impairment does not usually require a change in the administered dose.
Elderly patients are more likely to have age-related decreases in renal function. While the dose remains within the standard 5-10 mCi range, the physician will take the patient's overall hydration status and kidney health into account when interpreting the results.
Betiatide is not a medication you take at home. It is administered by a trained professional (usually a nuclear medicine technologist) in a hospital or imaging center.
Because Betiatide is administered for a scheduled diagnostic procedure by healthcare professionals, a missed dose is unlikely. If you miss your appointment, you must reschedule, as the radioactive component of the drug decays quickly and must be prepared fresh for each patient.
An overdose of the chemical Betiatide is extremely rare because the amount of powder in the vial (1 mg) is very small. A 'radiation overdose' is also highly unlikely due to the strict protocols and calibration of the dose before injection. In the event of an accidental administration of an excessive dose, the primary treatment is 'forced diuresis'—encouraging the patient to drink large amounts of fluids and urinate frequently to speed up the elimination of the radioactive material from the body.
> Important: Follow your healthcare provider's dosing instructions and pre-scan preparation carefully. Do not adjust your hydration levels or skip the procedure without medical guidance.
Adverse reactions to Betiatide are exceptionally rare. Unlike therapeutic drugs taken daily, Betiatide is a diagnostic agent given in a single, minute dose. Most patients experience no side effects at all. However, some patients may report:
These effects occur in a small percentage of patients and are usually mild:
Rarely, patients may experience more systemic reactions, which are often hypersensitivity-based:
While extremely rare, serious allergic reactions can occur.
> Warning: Stop the procedure and call your doctor immediately or seek emergency care if you experience any of these:
There are no known long-term 'chemical' side effects of Betiatide, as the drug is cleared from the body within hours. Regarding radiation, the dose received from a Betiatide scan is very low—comparable to or less than a standard CT scan or a year's worth of natural background radiation. While all radiation exposure carries a theoretical cumulative risk of cancer over many decades, the diagnostic benefit of the scan almost always outweighs this minimal risk.
No FDA black box warnings have been issued for Betiatide. It is considered a safe and well-tolerated diagnostic agent when used according to professional guidelines. However, it should only be administered by qualified personnel licensed to handle radioactive materials.
Report any unusual symptoms, even if they seem minor, to your healthcare provider or the nuclear medicine technologist during or after your scan. Reporting helps maintain the safety profile of these diagnostic tools.
Betiatide (as Technetium Tc-99m Mertiatide) is intended for diagnostic use only and has no therapeutic effect. It must be prepared and administered by professionals trained in the safe use and handling of radionuclides. To minimize radiation exposure to the patient and healthcare workers, the drug must be used in accordance with ALARA (As Low As Reasonably Achievable) principles. This means using the minimum dose necessary to achieve a clear diagnostic result.
There are currently no FDA black box warnings for Betiatide. Its safety profile is well-established for both adult and pediatric populations.
Because Betiatide is a one-time diagnostic agent, long-term lab monitoring is not required. However, during the procedure, the technologist will monitor:
Betiatide does not typically cause drowsiness or cognitive impairment. Most patients are able to drive themselves home and return to normal activities immediately after the scan. If you feel dizzy or unwell after the procedure, wait until the feeling passes before driving.
There are no known direct interactions between alcohol and Betiatide. However, alcohol is a diuretic and can cause dehydration, which may interfere with the accuracy of the kidney scan. It is best to avoid alcohol for 24 hours before the test.
As a single-dose diagnostic agent, there is no 'discontinuation' or 'withdrawal' associated with Betiatide. Once the scan is complete, the drug naturally leaves your system through your urine.
> Important: Discuss all your medical conditions, especially any history of kidney disease or severe allergies, with your healthcare provider before starting the Betiatide procedure.
There are no absolute drug-drug contraindications where the combination is 'deadly' or causes severe chemical toxicity. However, certain drugs must be avoided because they can make the test results impossible to interpret, leading to a misdiagnosis.
Betiatide does not typically interfere with standard blood or urine lab tests (like glucose or protein). However, because the patient will be 'radioactive' for about 24 hours, their urine may trigger radiation sensors, and certain specialized radioimmunoassays (rare lab tests) could be affected if blood is drawn immediately after the scan.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially blood pressure medications and diuretics.
There is no well-documented cross-sensitivity between Betiatide and iodine-based contrast dyes. Patients who are allergic to 'CT dye' can usually safely receive Betiatide. However, patients who have had reactions to other Technetium-labeled agents (like Tc-99m DTPA or Tc-99m MDP) should be approached with caution, as they may be sensitive to the stabilizers used in the kits.
> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to imaging tests, before prescribing a Betiatide-based scan.
Betiatide is classified by the FDA in Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether it can cause fetal harm. All radiopharmaceuticals have the potential to cause fetal radiation exposure. According to the Society of Nuclear Medicine and Molecular Imaging (SNMMI), if a renal scan is essential during pregnancy, Technetium Tc-99m Mertiatide is often preferred over other agents because it is cleared so rapidly by the mother's kidneys, which minimizes the time the fetus is exposed to radiation in the bladder.
Technetium Tc-99m is excreted in human milk. The Nuclear Regulatory Commission (NRC) and various medical societies recommend that breastfeeding be interrupted after the administration of Technetium Tc-99m Mertiatide. Typically, a 'pump and discard' period of 12 to 24 hours is advised. This ensures that the infant does not ingest radioactive material. Breast milk can be expressed prior to the scan and stored to feed the infant during this waiting period.
Betiatide is widely considered the 'gold standard' for renal imaging in children, including newborns. It is approved for use in pediatric patients of all ages. It is particularly useful for evaluating congenital (birth) defects like ureteropelvic junction (UPJ) obstruction or vesicoureteral reflux. Because children are more sensitive to radiation, the use of Betiatide (MAG3) is favored over I-131 Hippuran because it delivers a significantly lower radiation dose to the child's organs.
In elderly patients, the 'normal' range for renal function is lower than in younger adults. When interpreting a Betiatide scan in a patient over 65, the physician must account for age-related declines in the glomerular filtration rate (GFR) and tubular secretion. There is no evidence that elderly patients experience more side effects, but they should be encouraged to hydrate especially well, as they may be at higher risk for dehydration-related inaccuracies.
In patients with significant renal impairment, the clearance of Betiatide is slowed. This means the radioactive tracer stays in the body longer, and the images may appear 'faint.' However, Betiatide is often the preferred agent for these patients because its active secretion pathway allows for better visualization than agents that rely solely on passive filtration. No specific dose adjustment is required, but the imaging protocol may be modified (e.g., taking images for a longer duration).
No specific studies have been performed in patients with hepatic impairment. However, since the liver is not a primary route of elimination for this drug, no dosage adjustments are generally necessary. In rare cases of total renal failure, a very small amount of the drug may be excreted via the gallbladder, but this does not affect the safety of the drug.
> Important: Special populations, particularly pregnant women and nursing mothers, require an individualized medical assessment to ensure the safety of both the patient and the child.
Betiatide, once complexed with Technetium-99m to form Tc-99m Mertiatide, acts as a tracer for renal plasma flow. The molecule is a peptide-like chelate that carries a negative charge at physiological pH. It is highly protein-bound in the plasma (approx. 80-90%). As it enters the renal circulation, it is specifically recognized by the Organic Anion Transporters (OAT1 and OAT3) located on the basement membrane of the proximal renal tubule cells. These transporters actively pump the molecule from the blood into the cell, and then into the tubular lumen (the inside of the kidney tube). Because it is actively secreted and not reabsorbed, its clearance rate is a highly accurate reflection of the amount of blood being processed by the functional parts of the kidney.
Betiatide has no known pharmacodynamic effects at the doses used for imaging. It does not change blood pressure, heart rate, or kidney function. Its only 'action' is to emit gamma radiation (140 keV) from the Technetium-99m label, which can be detected by a gamma camera. The onset of action is immediate upon IV injection, with the kidneys typically becoming visible on the scan within 30 to 60 seconds. The peak concentration in the kidneys (Tmax) usually occurs within 3 to 5 minutes in a healthy individual.
| Parameter | Value |
|---|---|
| Bioavailability | 100% (Intravenous) |
| Protein Binding | 80% - 90% (Primarily Albumin) |
| Biological Half-life | 30 - 60 minutes |
| Tmax (Renal Peak) | 3 - 5 minutes |
| Metabolism | None (Excreted as intact chelate) |
| Excretion | Renal >90% (within 3 hours) |
Betiatide is classified as a diagnostic radiopharmaceutical ligand. Within the field of nuclear medicine, it is specifically categorized as a 'Renal Tubular Secretion Agent.' It is the primary alternative to Tc-99m DTPA (a glomerular filtration agent) and has largely replaced I-131 Orthoiodohippurate (Hippuran) in clinical practice due to its superior imaging characteristics and lower radiation dosimetry.
Common questions about Technetium Tc 99m Mertiatide
Betiatide is used to prepare a radioactive tracer called Technetium Tc-99m Mertiatide, which is essential for kidney imaging scans. These scans allow doctors to see how well your kidneys are functioning, how blood is flowing into them, and if there are any blockages in your urinary tract. It is commonly used to diagnose conditions like kidney stones, renal artery stenosis, or to check the health of a transplanted kidney. Because it is cleared very efficiently by the kidneys, it provides very clear pictures of the renal system. It is used in both adults and children for these diagnostic purposes.
Side effects from Betiatide are extremely rare because it is given in a very small, one-time dose. Some patients might notice a slight metallic taste in their mouth or a brief feeling of warmth or cold at the injection site. Occasionally, mild nausea or a headache may occur shortly after the injection, but these usually go away quickly on their own. Serious allergic reactions are possible but occur in fewer than 1 in 1,000 patients. Most people undergo the scan without feeling any different at all.
While there is no direct chemical interaction between alcohol and Betiatide, it is generally recommended to avoid alcohol for at least 24 hours before your scan. Alcohol is a diuretic and can lead to dehydration, which may change how your kidneys process the tracer and lead to inaccurate test results. For the most accurate scan, you should be well-hydrated with water rather than alcohol or caffeinated beverages. After the scan is complete and you have hydrated well to flush the tracer out, you can typically resume normal activities. Always check with your doctor for specific pre-scan instructions.
Betiatide is generally avoided during pregnancy unless the diagnostic information is critical and cannot wait until after delivery. It is classified as FDA Pregnancy Category C, meaning the risks to the unborn baby are not fully known. All radioactive substances carry a small risk of radiation exposure to the fetus. If a scan is absolutely necessary, Technetium Tc-99m Mertiatide is often the preferred choice because it leaves the mother's body very quickly, reducing the radiation time. Your doctor will perform a careful risk-benefit analysis before proceeding.
Betiatide works almost instantly once it is injected into your vein. Within 30 to 60 seconds, the tracer reaches your kidneys, and the gamma camera can begin capturing images of your blood flow. The 'peak' of the scan usually happens within 3 to 5 minutes, which shows the kidneys at their maximum filtering capacity. The entire imaging part of the procedure typically lasts between 20 and 30 minutes. You will receive the results after a radiologist or nuclear medicine physician interprets the recorded images.
You do not 'take' Betiatide in the way you take a daily pill, so there is no concern about stopping it suddenly. It is a one-time diagnostic injection administered by a healthcare professional. Once the injection is given and the scan is performed, the drug is naturally eliminated from your body through your urine within a few hours. There are no withdrawal symptoms or long-term effects associated with the drug. It is strictly a 'one-and-done' procedure for diagnostic purposes.
Because Betiatide is administered by a medical professional during a scheduled hospital or clinic appointment, you cannot 'miss a dose' at home. If you miss your scheduled imaging appointment, you will need to call the facility to reschedule. The radioactive component (Technetium-99m) has a very short shelf life and is prepared specifically for your appointment time. If you arrive late, the medication may have 'decayed' too much to be used, and a new dose will need to be prepared.
No, Betiatide does not cause weight gain. It is a diagnostic agent used in a single, microscopic dose (1 milligram of the ligand). It has no metabolic or hormonal effects on the body that would lead to changes in weight. Any weight changes you may be experiencing are likely due to your underlying medical condition or other medications you may be taking. If you have concerns about sudden weight gain, especially if you have kidney or heart issues, you should discuss them with your doctor immediately.
Betiatide can be used while you are taking most other medications, but some drugs can interfere with the accuracy of the scan. For example, blood pressure medicines like ACE inhibitors or diuretics (water pills) can change how your kidneys appear on the camera. It is very important to give your doctor a full list of your current medications before the scan. They may ask you to temporarily stop taking certain pills for 24 to 48 hours to ensure the test results are as accurate as possible.
Betiatide is the name of the active ingredient found in the brand-name kit 'Technescan MAG3.' While the term 'generic' is usually used for pills, there are different manufacturers of similar renal imaging kits globally. However, in the United States, most facilities use the standardized kits approved by the FDA. Because it is a specialized radiopharmaceutical used only in hospitals, you won't find a generic version at a retail pharmacy. The cost of the drug is usually included in the overall price of the diagnostic imaging procedure.
Other drugs with the same active ingredient (Betiatide)